Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients

Transplantation

Volumn 83, Issue 5, 2007, Pages 645-648

  Oppenheimer, Federico ^a   Mulgaonkar, Shamkant ^b   Ferguson, Ronald ^c   Grinyó, Josep ^d   Juarez, Federico ^e   Ostrowski, Marek ^f   Klinger, Marian ^g   Walker, Rowan ^h   Torres, Armando ⁱ   Preiss, Ralph ^j   Cremer, Malika ^j   Jardine, Alan ^k  

^a HOSPITAL CLÍNIC   (Spain)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL DE ESPECIALIDADES   (Mexico)

^f Klinika Chirurgii Ogolnej i T   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j NOVARTIS PHARMA AG   (Switzerland)

^k WESTERN INFIRMARY   (United Kingdom)

more..

Author keywords

Cardiac rhythm; Cyclosporine; FTY720; Mycophenolate mofetil; Renal transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; FINGOLIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART CONDUCTION; HEART RATE; HEART RHYTHM; HEART VENTRICLE HYPERTROPHY; HOLTER MONITORING; HUMAN; KIDNEY GRAFT; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TACHYCARDIA; TORSADE DES POINTES;

ADRENERGIC ANTAGONISTS; ADULT; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 33947314300     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000253421.18892.b8     Document Type: Article

References (13)

1. Brinkmann V, Lynch KR. FTY720: Targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569.
2. Brinkmann V, Davies MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453.
3. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 2002; 296: 346.
4. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073.
5. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter randomized, placebo-controlled, phase I study. Transplantation 2003; 76: 1079.
6. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79: 1553.
7. Mulgaonkar S, Tedesco H, Oppenheimer F, et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant 2006; 6: 1848.
8. Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect of cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006; 46: 895.
9. Kappos L, Radue EW, Antel J, et al. FTY720 in relapsing MS: results of a double-blind placebo-controlled trial with a novel oral immunomodulator. Presented at the European Neurological Society, Vienna, Austria, June 18-22, 2005.
10. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 (S1P1) in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019.
11. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529.
12. Licht T, Tsirulnikov L, Reuveni H, et al. Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 2003; 102: 2099.
13. Graler MH, Goetzl EJ. The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18: 551.